SCHEMBL30186396

SCHEMBL30186396

Cn1ccc(=O)c2cc(O)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
KDM6A O15550 1/20 0.44
KDM4A O75164 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KDM5C P41229 1/20 0.44
KDM2B Q8NHM5 1/20 0.44
DOHH Q9BU89 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
WEE1 P30291 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
BCHE P06276 2/20 0.39
ACHE P22303 2/20 0.39
SPR P35270 1/20 0.39
GAA P10253 3/20 0.38
ALOX5 P09917 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186358 0.85 KDM4E (0.44) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL24151235 0.79 PGR (0.42) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL15992161 0.79 KDM4E (0.46) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL2996296 0.78 PRKCI (0.56) KDM4EKDM6AKDM4ACYP2C9CYP2C19
SCHEMBL10627404 0.78 KDM4E (0.51) KDM4EALOX5ALDH1A1MEN1KMT2A
SCHEMBL31337024 0.77 KDM4E (0.51) KDM4EALDH1A1KMT2AHPGD
SCHEMBL2990303 0.73 MAPT (0.53) KDM4ESMN1; SMN2MEN1KMT2ALMNA
SCHEMBL1400341 0.72 PRKCI (0.59) KDM4ECYP2C19GAAALDH1A1SMN1; SMN2
SCHEMBL29874172 0.72 PRKCI (0.59) KDM4ECYP2C19GAAALDH1A1SMN1; SMN2
SCHEMBL1809581 0.72 ALDH1A1 (0.59) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522597-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2026-01-13 US disclosed
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 KDM4E 2544/4885KDM6A 2375/4885KDM4A 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.